SCHEMBL5841303

SCHEMBL5841303

O=C(Nc1ccc2c(c1)Cc1ccccc1-2)C1CC(=O)N(CCc2ccccc2)C1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.66
LMNA P02545 3/20 0.55
HPGD P15428 1/20 0.55
ALDH1A1 P00352 5/20 0.53
POLB P06746 4/20 0.52
KMT2A Q03164 2/20 0.52
TP53 P04637 2/20 0.52
MEN1 O00255 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
GLA P06280 1/20 0.51
MAPT P10636 1/20 0.51
KDM4E B2RXH2 1/20 0.51
CYP2D6 P10635 1/20 0.50
SMAD3 P84022 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842682 0.86 SMN1; SMN2 (0.68) SMN1; SMN2LMNAHPGDALDH1A1POLB
SCHEMBL6611018 0.84 SMN1; SMN2 (0.47) SMN1; SMN2LMNAHPGDPOLBKMT2A
SCHEMBL5841099 0.84 ALDH1A1 (0.51) SMN1; SMN2LMNAHPGDALDH1A1KMT2A
SCHEMBL5842500 0.81 SMN1; SMN2 (0.70) SMN1; SMN2LMNAHPGDALDH1A1POLB
SCHEMBL5843962 0.81 SMN1; SMN2 (0.69) SMN1; SMN2LMNAHPGDALDH1A1POLB
SCHEMBL5842481 0.81 SMN1; SMN2 (0.69) SMN1; SMN2LMNAHPGDALDH1A1POLB
SCHEMBL5843822 0.81 CA12 (0.59) SMN1; SMN2LMNAALDH1A1POLBKMT2A
SCHEMBL5842699 0.79 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL5841720 0.79 SMN1; SMN2 (0.66) SMN1; SMN2LMNAHPGDALDH1A1POLB
SCHEMBL5842312 0.78 ALDH1A1 (0.66) SMN1; SMN2LMNAHPGDALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R SMN1; SMN2 3678/4885LMNA 3430/4885HPGD 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.